Recombinant Human DLL3 Protein (C-His)

Measured by functional ELISA. Immobilized recombinant human DLL3 binds reference anti-DLL3 antibody (tarlatamab class) with an EC50 in the range of 10–50 ng/mL.

DLL3 (Delta-like canonical Notch ligand 3) is an atypical Notch-family ligand that, uniquely among its relatives, inhibits canonical Notch signaling and is sequestered intracellularly in most tissues. In neuroendocrine tumors — above all small-cell lung cancer — DLL3 re-emerges on the cell surface at high density with minimal normal-tissue expression, making it an almost ideal tumor-restricted target. That biology underwrote tarlatamab, the first DLL3×CD3 bispecific T-cell engager approved for SCLC, alongside earlier rovalpituzumab tesirine ADC learnings. The full extracellular domain spanning the DSL and EGF-like repeats presented here supports bispecific screening, potency assay development and DLL3 diagnostic reagent work.